Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open-label, Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type, MGMT Unmethylated Glioblastoma

NCT05871021 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT05871021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05871021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open-label, Multicenter Study of Radiochemotherapy With Isotoxic Dose Escalation and Protective VEGF Inhibition Using Bevacizumab in the Treatment of Patients With First Diagnosis of IDH Wild-type, MGMT Unmethylated Glioblastoma
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 10, 2024
Completion date
April 15, 2029
Enrollment
107 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma